Literature DB >> 23809244

Precancerous lesions in inflammatory bowel disease.

Noam Harpaz1, Stephen C Ward, Claudia Mescoli, Steven H Itzkowitz, Alexandros D Polydorides.   

Abstract

Reduction of mortality from colorectal cancer is a prime goal in the clinical management of patients with extensive, longstanding ulcerative colitis and colonic Crohn's disease. The cornerstone of current cancer prevention efforts is endoscopic surveillance for colorectal dysplasia, or intraepithelial neoplasia, the direct histological precursor of cancer. A diagnosis of dysplasia provides a reliable indicator of heightened cancer risk and an end-point for colonoscopic surveillance allowing most patients to undergo prophylactic colectomy before the development of incurable cancer. This article reviews the classification, pathological criteria and clinical implications of colorectal dysplasia, current recommendations for the performance of surveillance colonoscopy, recent technical advances in colonoscopic imaging to enhance the detection of dysplasia, and a summary of the molecular genetic events implicated in its development.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23809244     DOI: 10.1016/j.bpg.2013.03.014

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  14 in total

Review 1.  Precancer in ulcerative colitis: the role of the field effect and its clinical implications.

Authors:  Kathryn T Baker; Jesse J Salk; Teresa A Brentnall; Rosa Ana Risques
Journal:  Carcinogenesis       Date:  2018-01-12       Impact factor: 4.944

Review 2.  Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

Authors:  Bruno Christian Koehler; Dirk Jäger; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

3.  Immunohistochemical expression of SP-NK-1R-EGFR pathway and VDR in colonic inflammation and neoplasia.

Authors:  Raymond A Isidro; Myrella L Cruz; Angel A Isidro; Axel Baez; Axel Arroyo; William A González-Marqués; Carmen González-Keelan; Esther A Torres; Caroline B Appleyard
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

4.  Neuropeptide Y (NPY) promotes inflammation-induced tumorigenesis by enhancing epithelial cell proliferation.

Authors:  Sabrina Jeppsson; Shanthi Srinivasan; Bindu Chandrasekharan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-17       Impact factor: 4.052

Review 5.  Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.

Authors:  Marica Garziera; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

6.  Serrated colorectal polyps in inflammatory bowel disease.

Authors:  Huaibin M Ko; Noam Harpaz; Russell B McBride; Miao Cui; Fei Ye; David Zhang; Thomas A Ullman; Alexandros D Polydorides
Journal:  Mod Pathol       Date:  2015-09-25       Impact factor: 7.842

Review 7.  Ulcerative colitis: from inflammation to cancer. Do estrogen receptors have a role?

Authors:  Mariabeatrice Principi; Michele Barone; Maria Pricci; Nicola De Tullio; Giuseppe Losurdo; Enzo Ierardi; Alfredo Di Leo
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 8.  Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.

Authors:  Xinyun Qiu; Jingjing Ma; Kai Wang; Hongjie Zhang
Journal:  Oncotarget       Date:  2017-01-03

Review 9.  Assessment of thyroid cancer risk in more than 334,000 patients with inflammatory bowel disease: a case-control study and a meta-analysis.

Authors:  Lihong Cao
Journal:  World J Surg Oncol       Date:  2018-09-10       Impact factor: 2.754

Review 10.  Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment.

Authors:  Moses M Kasembeli; Uddalak Bharadwaj; Prema Robinson; David J Tweardy
Journal:  Int J Mol Sci       Date:  2018-08-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.